Legacy Wealth Asset Management LLC Lowers Stake in Genmab A/S Sponsored ADR $GMAB

Legacy Wealth Asset Management LLC cut its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 52.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 22,028 shares of the company’s stock after selling 24,559 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Genmab A/S were worth $678,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Osaic Holdings Inc. raised its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. NewEdge Advisors LLC grew its holdings in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares during the period. Brown Brothers Harriman & Co. increased its position in shares of Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares in the last quarter. AlphaCore Capital LLC purchased a new stake in shares of Genmab A/S in the second quarter valued at approximately $44,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $25.81 on Wednesday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $35.43. The firm has a market capitalization of $16.58 billion, a PE ratio of 16.65, a P/E/G ratio of 1.05 and a beta of 0.94. The business’s 50 day moving average price is $29.87 and its 200-day moving average price is $30.53.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. As a group, equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GMAB. HC Wainwright increased their target price on Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 price objective for the company. Wells Fargo & Company initiated coverage on shares of Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective on the stock. Guggenheim dropped their target price on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, February 23rd. Finally, Morgan Stanley started coverage on shares of Genmab A/S in a research note on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.58.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.